Skip to main navigation
  • Home
  • We are ProQR
    • About us
    • Vision 2023
    • Leadership
    • Careers
    • Contact
  • Science & Pipeline
    • Research and development pipeline
    • Clinical Trials
      • QR-421a STELLAR phase 1/2 study for Usher syndrome
      • Sepofarsen ILLUMINATE phase 2/3 study for LCA10
      • Sepofarsen INSIGHT – phase 1b/2 study for LCA10
      • Sepofarsen Study 001 phase 1/2 for LCA10
    • Sepofarsen for Leber’s congenital amaurosis 10
    • QR-421a for Usher syndrome type 2
    • QR-1123 for autosomal dominant retinitis pigmentosa
    • Axiomer RNA editing platform technology
    • Spin outs
      • Wings Therapeutics
      • Amylon Therapeutics
  • Community
    • Patient and Medical Community Engagement
    • Eye Connect Newsletter
    • Stories
  • News & Publications
    • Press Releases
    • Posters & Publications
    • ProQR in the Media
    • Press kit
  • Investors

    Investor Relations

    • Investor Home
    • Investor Home
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Financial Information
    • Share Performance
    • Analysts
    • FAQ
    • Email Alerts
    • IR Contacts
  • Facebook
  • Twitter
  • LinkedIn
  • Home
  • We are ProQR
    • About us
    • Vision 2023
    • Leadership
    • Careers
    • Contact
  • Science & Pipeline
    • Research and development pipeline
    • Clinical Trials
      • QR-421a STELLAR phase 1/2 study for Usher syndrome
      • Sepofarsen ILLUMINATE phase 2/3 study for LCA10
      • Sepofarsen INSIGHT – phase 1b/2 study for LCA10
      • Sepofarsen Study 001 phase 1/2 for LCA10
    • Sepofarsen for Leber’s congenital amaurosis 10
    • QR-421a for Usher syndrome type 2
    • QR-1123 for autosomal dominant retinitis pigmentosa
    • Axiomer RNA editing platform technology
    • Spin outs
      • Wings Therapeutics
      • Amylon Therapeutics
  • Community
    • Patient and Medical Community Engagement
    • Eye Connect Newsletter
    • Stories
  • News & Publications
    • Press Releases
    • Posters & Publications
    • ProQR in the Media
    • Press kit
  • Investors
  • Investor Relations

    • Investor Home
    • Investor Home
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Financial Information
    • Share Performance
    • Analysts
    • FAQ
    • Email Alerts
    • IR Contacts
  • Facebook
  • Twitter
  • LinkedIn
lab04s4

IR Contacts

IR Contacts

ProQR Therapeutics N.V.
Phone: +31 88 166 7000
E-mail: info@proqr.com
 
Hans Vitzthum
LifeSci Advisors
Phone: +1 617 535 7743
E-mail: hans@lifesciadvisors.com
 

Media Contact

Sariette Witte
Director Corporate Communications
E-mail: pr@proqr.com

Investor Relations

  • Investor Home
  • Investor Home
  • Press Releases
  • Events and Presentations
  • Corporate Governance
  • Financial Information
  • Share Performance
  • Analysts
  • FAQ
  • Email Alerts
  • IR Contacts
© 2019 ProQR Therapeutics. All Rights Reserved.
ProQR is a registered trademark. Disclaimer | Privacy Policy